User profiles for Harry Hollema

Harry Hollema

Professor of Pathology, UMCG Groningen Netherlands
Verified email at ziggo.nl
Cited by 23720

Risk and prognosis of endometrial cancer after tamoxifen for breast cancer

L Bergman, MLR Beelen, MPW Gallee, H Hollema… - The Lancet, 2000 - thelancet.com
Background Tamoxifen increases the risk of endometrial cancer. However, few studies have
produced reliable risk estimates by duration, dose, and recency of use, or addressed the …

[HTML][HTML] Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label …

…, W Taylor, RFPM Kruitwagen, H Hollema… - The lancet …, 2018 - thelancet.com
Background Although women with endometrial cancer generally have a favourable prognosis,
those with high-risk disease features are at increased risk of recurrence. The PORTEC-3 …

[HTML][HTML] Prognostic significance of tumor-infiltrating T-lymphocytes in primary and metastatic lesions of advanced stage ovarian cancer

…, BN Hoogeboom, KA ten Hoor, H Hollema… - Cancer Immunology …, 2009 - Springer
Purpose Ovarian cancer patients with intra-tumoral CD3 + T-lymphocytes in primary tumor
tissue have a better prognosis. This study aims to analyze the presence and relative influence …

In vivo VEGF imaging with radiolabeled bevacizumab in a human ovarian tumor xenograft

…, NH Mulder, JR De Jong, H Hollema… - Journal of Nuclear …, 2007 - Soc Nuclear Med
Vascular endothelial growth factor (VEGF), released by tumor cells, is an important growth
factor in tumor angiogenesis. The humanized monoclonal antibody bevacizumab blocks VEGF…

Vulvar carcinoma: the price of less radical surgery

JA De Hullu, H Hollema, S Lolkema… - … Journal of the …, 2002 - Wiley Online Library
The standard radical treatment of patients with early‐stage vulvar carcinoma has changed
to wide local excision and inguinofemoral lymphadenectomy through separate incisions, …

[PDF][PDF] Association of hereditary nonpolyposis colorectal cancer–related tumors displaying low microsatellite instability with MSH6 germline mutations

…, RH Sijmons, AGJ van der Zee, H Hollema… - The American Journal of …, 1999 - cell.com
Hereditary nonpolyposis colorectal cancer (HNPCC) (Amsterdam criteria) is often caused
by mutations in mismatch repair (MMR) genes, and tumors of patients with HNPCC show …

Tamoxifen treatment and gynecologic side effects: a review

…, PHB Willemse, KA Ten Hoor, H Hollema… - Obstetrics & …, 2001 - journals.lww.com
… Mourits, Marian JE MD; De Vries, Elisabeth GE MD, PhD; Willemse, Pax HB MD, PhD;
Ten Hoor, Klaske A.; Hollema, Harry MD, PhD; Van der Zee, Ate GJ MD, PhD …

Size of sentinel-node metastasis and chances of non-sentinel-node involvement and survival in early stage vulvar cancer: results from GROINSS-V, a multicentre …

MH Oonk, BM van Hemel, H Hollema… - The lancet …, 2010 - thelancet.com
Background Currently, all patients with vulvar cancer with a positive sentinel node undergo
inguinofemoral lymphadenectomy, irrespective of the size of sentinel-node metastases. Our …

[PDF][PDF] Molecular and clinical characteristics of MSH6 variants: an analysis of 25 index carriers of a germline variant

…, JM Hordijk-Hos, EGE de Vries, H Hollema… - The American Journal of …, 2002 - cell.com
The MSH6 gene is one of the mismatch-repair genes involved in hereditary nonpolyposis
colorectal cancer (HNPCC). Three hundred sixteen individuals who were known or suspected …

Tissue distribution of the death ligand TRAIL and its receptors

…, JJ Koornstra, J Wesseling, H Hollema… - … of Histochemistry & …, 2004 - journals.sagepub.com
Recombinant human (rh) TNF-related apoptosis-inducing ligand (TRAIL) harbors potential
as an anticancer agent. RhTRAIL induces apoptosis via the TRAIL receptors TRAIL-R1 and …